The Developments of Drugs Based on Non-Alcoholic Fatty Liver

DOI

10.2991/978-2-38476-295-8_17How to use a DOI?

Keywords

NAFL; ACC; DGAT2; SGLT2; GLP-1/GIP; PPAR

Abstract

Non-Alcoholic Fatty Live (NAFL), a serious hepatopathy with a rising global prevalence, characterized through the simple excessive proliferation of triglyceride (TG) in the liver. It is triggered by an imbalance in fat metabolism by the reason of adiposity, fat-rich diet and insulin resistance (IR). The targets of treatment are to improve liver fat and function, focusing on the regulation of fat synthesis, metabolism and IR. This article mainly introduces the pathogenesis, therapeutic effect and development prospect of SGLT2 inhibitors, GLP-1/GIP analogues, ACC inhibitors, DGAT2 inhibitors and PPAR agonists which related to the above pathways in the therapies of NAFL diseases. Fortunately, these drugs corresponding to the targets have offered new strategies for the cure of NAFL.

Copyright

© 2024 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Sihang Chen
AU  - Ming Chu
PY  - 2024
DA  - 2024/10/21
TI  - The Developments of Drugs Based on Non-Alcoholic Fatty Liver
BT  - Proceedings of the 4th International Conference on Public Administration, Health and Humanity Development (PAHHD 2024)
PB  - Atlantis Press
SP  - 136
EP  - 150
SN  - 2352-5398
UR  - https://doi.org/10.2991/978-2-38476-295-8_17
DO  - 10.2991/978-2-38476-295-8_17
ID  - Chen2024
ER  -